Bioventus (BVS) Other Non-Current Liabilities (2021 - 2026)

Bioventus (BVS) has 6 years of Other Non-Current Liabilities data on file, last reported at $14.3 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 35.02% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (down 35.02% YoY) and the FY2025 annual result came in at $15.3 million, down 33.56% from the prior year.
• Other Non-Current Liabilities retreated to $14.3 million in Q1 2026, from $15.3 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $30.9 million in Q3 2023 to a low of $14.3 million in Q1 2026.
• A 5-year average of $21.1 million and a median of $21.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 60.25% — and 2026, when it slumped 35.02%.
• Tracing BVS's Other Non-Current Liabilities over 5 years: stood at $17.4 million in 2022, then jumped by 60.25% to $27.9 million in 2023, then fell by 17.3% to $23.1 million in 2024, then tumbled by 33.56% to $15.3 million in 2025, then retreated by 6.93% to $14.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $14.3 million (Q1 2026), $15.3 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.